Source comparison
Nasal vs Subcutaneous: When Each Route Matters
Subcutaneous injection remains the most reliable method for achieving consistent systemic MOTS-c levels across repeated doses. Bioavailability approaches 90–95% because the peptide deposits directly into interstitial fluid, bypassing all epithelial barriers. P
This comparison does not assign a generated winner or score.
- Subcutaneous injection remains the most reliable method for achieving consistent systemic MOTS-c levels across repeated doses. Bioavailability approaches 90–95% because the peptide deposits directly into interstitial fluid, bypassing all epithelial barriers. Pharmacokinetic curves are predictable: peak plasma concentration occurs 30–60 minutes post-injection, with a half-life of approximately 2–3 hours for unmodified MOTS-c.
- When you use MOTS-c nasally, bioavailability is lower. 40–60% in most peptide studies. But the trade-off is convenience and CNS access. Nasal administration doesn't require sterile technique, reconstitution with bacteriostatic water, or injection supplies. For research applications prioritizing ease of administration or hypothalamic signaling, nasal delivery offers compelling advantages.
- One critical limitation: nasal absorption capacity is finite. The nasal mucosa can only absorb approximately 25–50 mg of peptide per dose before saturation occurs and excess peptide drains into the nasopharynx, where it's swallowed and degraded. MOTS-c doses in research contexts typically range from 5–15 mg per administration, well within this capacity. Subcutaneous injection has no comparable absorption ceiling. Doses up to 100 mg have been studied without saturation effects.
- Our team has found that researchers using MOTS-C Nasal Spray report more consistent daily adherence compared to injectable protocols. Injection fatigue. Reluctance to self-administer needles over weeks or months. Is real. Nasal delivery eliminates this entirely.